

Index

- abdominal circumference stretching, 171–2
- actin–myosin fibres, 59
- adaptability of tissues, 160
- adipose tissue, 145
- adult tissue growth, mechanically induced, 171–2
- agarose, 90
- aims of TERM, 33–7, 49
 - clinical implant tissues, 46–7
 - opportunities from diversity, 48–9
 - pathological and aphysiological constructs, 47–8
 - physiological implants, 47
 - opportunities, risks and problems, 41
 - experimental model tissues, 41–2
 - experimental model tissues and implants, 42–4
 - experimental model tissues, 3D, 42
 - overambition, 39–41
 - special needs of model tissues
 - cell selection, 44–5
 - support matrices, 45–6
 - tissue size, 46
 - special tissue needs, 37–9
- aircraft engineering analogy, 33–7
- alginates, 90
- aligning dehydration, 92
- allogenic cells, 118
- allografts, 2
- amphibians, tissue regeneration, 20–1
- anchorage of cells, 62
- angiogenesis, 22, 156
- animal testing, 42
- aphysiological constructs, 47–8
- architecture–control assumption, 186
- areolar tissue, 145
- aseptic conditions, 202
- asymmetry, 131–3, 159–60
 - cell-layering and matrix-layering, 147–51
 - degrees of tissue asymmetry, 133–4
- familiar construction components, 159
- hierarchical complexity, 144–7
- other fabrication forms, 157–9
- scale selection, 140–4
- simple anisotropic/asymmetric structures, 134–7
- thinking asymmetrically, 137–40
- tissue layer engineering, 151–3
 - examples, 153–7
- atelocollagen, 95–6
- atomic forces, 4–5
- autografts, 2
- autologous cells, 118
- axon migration, 115
- bedside graft delivery of tissues, 231
- bending finger, 26
- bio-complexity, 4
- biodegradability, 89
- biodegradable polymers, 86
- bioglass, 89
- bio-integration, 7–8
 - diversity of background, 8–10
- biological materials, 86
- biology ‘tribe’ of tissue engineering, 7
- bio-mimetic engineering, 39
- bio-printing, 150–1
- bioreactors, 186
 - current strategies, 199–200
 - cell and architecture control, 203–8
 - enabling factors, 200–3
 - future directions, 212–14
 - rationale
 - biochemical versus tissue bioreactors, 193–4
 - matrix considerations, 194–5
 - role in tissue engineering, 195–9
 - three-dimensional considerations, 191–2
 - tissue engineering, 190–1
 - special cells or special cues, 187–8
- tissue engineering solutions, 209
 - in vivo* versus *in vitro* bioreactors, 209–10, 211–12
 - logic summary, 212
 - need for bioreactors, 210–12
- blood, 94
- bone growth, 169
- bone marrow stromal cells, 120
- bottom-up fabrication, 107–10
- bottom-up logic, 19
- bottom-up processed tissues, 97
- bulk contact support materials, 85, 87
- cadaveric transplants, 1–2, 47
- cell adaptive changes, 71
- cell and developmental biology, 118
- cell-control cues, 186
- cell-controlled systems, 86
- cell-dependent breakdown, 86
- cell engineering, 6
- cell-independent breakdown, 86
- cell-layering, 147–51
- cell multiplication, 121–4
- cell numbers, 230
- cell prosthetics, 83–5
- cell-rich tissues, 47, 169
 - cultures, 69–71
- cell-seeding, 79–80
 - interstitial three-dimensional, 87
- cell signals, 87
- cell-space forms
 - diffusion and mass transport, 65–6
 - extracellular matrix, 63–5
 - four-dimensional cultures, 71–3
 - matrix-rich, cell-rich and pseudo-3D cell cultures, 69–71
 - oxygen mass transport, 66–9
 - three-dimensional, 62–3
- cell therapies, 6, 26
- cells, shape and size, 142
- channelling/microchannelling, 156, 200, 228

- childhood tissue growth, 169–70
 mechanically induced, 170–1
 possibility of reversal, 174
- chitin (chitosan), 90
- collagen, 94–8
 bottom-up assembly, 109
 fibrils, 104, 105, 142–4
 engineering, 155–6
 tensile properties, 208
 mechanically reactive, 177–8
 size scale, 5
- collagen plastic compression (CPC), 148–50
- collagen-GAG sponges, 97
- complexity, 139
 hierarchical, 144–7
- compositional heterogeneity, 139
- compositional inhomogeneity, 138
- concentration gradients, 65
- constant tailor theory, 177–8
- construct perfusion, 199, 200
- cross-disciplinary working, 8, 13
- cytoskeletons, 59
- dermal repair, 97
- dermal scarring *see* scarring
- dermis, 145, 147
- design approach, 221
- destructive testing, 242–3
- diffusion, 65–6
- direct explicit, end-function measures, 219
- direct fabrication of tissues, 248
- direct tissue engineering (DTE), 222
 process design graph, 229
- Dupuytren's disease, 26
- dynamic load patterns, 181
- earthworms, 53–4
- electrospinning, 158
- end-stage monitoring, 245
- engineering 'tribe' of tissue engineering, 7
- epidermis, 145–6, 147
- epithelial cells, 56–7
 stratification, 58
 structures, 60
- essential features of engineering tissues, 242
- EU collaborative and networking activities, 16, 17
- excess information, 60–1
- explicit/direct tests, 242
- extracellular matrix (ECM), 63–5, 141, 143
- cell-derived, 227–8
- extreme tissue engineering (ETE), 247
- farming, 188–90
- fibrinogen/fibrin, 93–4
- fibroblast growth factor (FGF), 99, 100
- fibroblasts, 145
- fibronectin, 92–3
- fixed flexion deformity, 26
- fluid-leaving surface (FLS), 117
- forces, 205
- four-dimensional cell cultures, 71–3
- four-dimensional fabrication, 217–18, 245–6
- bioreactor design
 bioreactor monitoring, 233–4
 continuous change, 232–3
 monitoring and processes, 234–8
 control of dynamics, 218–22
 monitoring procedure, 238
 identifying importance, 241–5
 parameter selection, 238–40
 other processes, 222
 blending systems, 222–5
 direct tissue manufacture, 230–2
 hybrid strategies, 225–30
- functional compromise, 40
- function-based design, 38
- gallon (as an example of historical divergence of definition), 4
- gelatine, 96
- gene knock-out, 35
- gradients, 65
- growth, nature of, 167–9
 adult growth, mechanically induced, 171–2
 childhood growth, 169–70
 mechanically induced, 170–1
 shrinkage remodelling, 172–3
- Harvey, William, 18
- heterogeneous cell populations, 45
- hierarchical complexity, 144–7
- hip replacements, 2
- Hippocrates, 187
- hyaluronan (hyaluronic acid), 91–2
- hydrogels, 116, 117
- hypodermis, 145, 147
- implants, 46–7
 pathological and aphysiological constructs, 47–8
 physiological, 47
- indirect tissue engineering (ITE), 222
 process design graph, 227
- indirect, implicit measures, 219
- indirect/implicit tests, 242
- inducible pluripotent stem (IPS) cells, 187, 221
- insoluble collagen materials, 95
- Instron-based compression bioreactor, 206
- integration of tissues, 21, 22
- intellectual safety, 14
- intelligent design of cell supports, 88
- interfaces, 138
- internal forces of cells, 64
- interstitial 3D cell seeding, 87, 109, 110–11
 cell loading, 111–14
 cell positioning, 114–15
 self-assembling, gel-forming materials, 115–18
- invasive monitoring, 243–4
- keratinocytes, 145
- Key Functional Properties (KFPs), 37–8
- knowledge-matrix, 15
- layer engineering, 139–40, 147–51, 159–60
 familiar construction components, 159
 other fabrication forms, 157–9
 theory and practice, 151–3
 examples, 153–7
- Linnaeus, Carl, 18, 19
- living tissue grafts, 1–2
- lost-fibre μ -channelling technique, 156
- mass production tissue production, 231–2
- mass transport, 65–6
- matrix diffusion coefficient, 65
- matrix-layering, 147–51
- matrix-rich tissues, 47, 169
 cultures, 69–71
- measuring changes, 218
- mechanical integration/attachment, 22
- mechanical surface signals, 87
- mechano-bioreactors, 205, 209
- mechano-dependent tissue remodelling, 182
- meso scale forces, 5
- micro scale forces, 5
- microchannelling *see* channelling
- micro-porous cell support scaffolds, 119

- model tissues, 41–2
 cell selection, 44–5
 implants, 42–4
 size, 46
 support matrices, 45–6
 three-dimensional, 42
 molecular forces, 4–5
 monolayer cell culture, 179
 monolayers of cells, 56, 62
- nano scale forces, 4
 nano-porous cell support scaffolds, 119
 natural materials, 86
 natural polymers for cell supports, 90
 polysaccharides, 90–2
 proteins, 92
 natural tissue repair, 165, 166–7
 networking across biotechnological fields, importance of, 13–16
 non-animal testing, 43
 non-destructive testing, 243
 non-invasive monitoring, 243–4
 non-linear interfaces, 138
 nursery implant sites, 210–11
- obesity, 171
 osteochondral interface engineering, 156
 osteoporosis, 174
 Out Of Plane Stimulation (OOPS), 178, 182
 oxygen mass transport, 66–9
- papillar region, 145
 path length, 65
 pathological constructs, 47–8
 perfusion, 69, 156, 191, 200–2, 203, 229
 perfusion-led bioreactor design, 207–8
 phantom limb effect, 22
 phenotype changes, 35
 planes of human asymmetry, 133, 134
 plasma (of the blood), 94
 plastic compression of cells, 117
 platelet-derived growth factor (PDGF), 99
 platforms, 15
 poly(lacto-*co*-glycolic acid) (PLGA), 88–9
 poly-N-isopropylacrylamide, 148
 polysaccharides as cell supports, 90–2
 porosity of support-scaffolds, 82
 post-fabrication seeding, 110
 primary cultures, 45
 priorities for support-scaffolds, 82–3
 process design graphs
 direct tissue engineering, 229
 indirect tissue engineering, 227
 process monitoring
 evolving, 240
 targets, 237
 process sequence, 223
 prosthetic implants, 1–2, 164
 proteins as cell supports, 92
 pseudo-3D cell cultures, 69–71
 pulsing flow bioreactor, 206
- radial interfaces, 138
 real-time monitoring, 245
 oxygen, 244
 reconstructive surgery, 165–6
 regeneration, 146
 regeneration of tissues, 1, 20
 differences from repair, 24
 re-innervation, 22
 rejection of transplants, 2
 repair of tissues, 20
 differences from regeneration, 24
 Repetitions, Interfaces and Polarities (RIP), 139
 resolution and number of layers, 157
 reticular region, 145
 revascularization, 22
 RGD peptides, 98
 rotating wall bioreactor, 207
- safe-hype tension, 39–41
 salamanders, limb regeneration, 20–1
 scale of engineering
 caveats, 140, 141
 order, 140–4
 scale-hierarchy
 definition, 4–7
 forces, 205
 scarring, 23, 27
 serum, 94
 shapes for cells in support-scaffolds,
 103–4, 128
 bottom-up or top-down fabrication,
 107–10
 cell acquisition, 118–21
 expansion, selection and
 differentiation, 121–4
 cell types, 124
 ballast cells, 128
 bulk tissue cells, 125–8
 scaffolding cells, 124–5
 control by substrate shape, 106–7
 seeding, 110–11
 cell loading, 111–14
 cell positioning, 114–15
- sell-assembling, gel-forming materials, 115–18
 three-dimensional shape and size hierarchy, 104–6
 sharks, 54
 shrinkage remodelling, 172–3
 silks, 92
 skates, 54
 skin, 145–7
 balanced tension, 167
 growth, 166
 skin implants and grafts, 42
 skin-equivalent models, 43
 skin-stretching experiment, 81–2
 soft connective tissues, childhood growth, 170
 ‘someone else’s problem’ (SEP principle), 221
 spatial homogeneity, 139
 spatial perception, 74–5
 cell-space forms
 diffusion and mass transport, 65–6
 extracellular matrix, 63–5
 four-dimensional cultures, 71–3
 matrix-rich, cell-rich and pseudo-3D cell cultures, 69–71
 oxygen mass transport, 66–9
 three-dimensional, 62–3
 sensing the environment, 51–4
 three-dimensional cell culture, 54–5
 three-dimensional versus two-dimensional structures, 55–8
 understanding cell position in 3D space, 73–4
 starch, 90
 stem-progenitor cell biology, 118
 sterile conditions, 202–3
 strata of the epidermis, 145
 stress shielding, 84
 stretch marks, 172
 stroma, 145
 stromal cells, 57, 58
 structures, 60
 structural repetition, 138
 support matrices, 45–6
 support-scaffolds for living cells, 100–1
see also shapes for cells in support-scaffolds
 bulk support types, 86–8
 hybrids, 98–100
 natural polymers, 90–8
 synthetic materials, 88–90
 materials, 85
 bulk material breakdown, 85–6

- support-scaffolds for living cells,
 - (continued)
 - surface versus bulk support, 85, 87
 - selection, 78–80
 - similarity to living systems, 80–3
 - synergy, 77–8
 - tissue prosthetics and cell prosthetics, 83–5
- surface chemical signals, 87
- surface contact support materials, 85, 87
- surface-fabrication seeding, 110
- syncytia, 125
- synthetic materials for cell supports, 88–90

- tensile forces within cells, 64
- tensional homeostasis, control of, 173–4
 - cell-directed, 174–7
 - mechanically reactive collagen remodelling, 177–8
- tension-driven growth processes, 171
- three-dimensional sensing, 52
 - cell culture, 54–5
 - cell environment, 58–61
 - cell-space forms, 62–3
 - diffusion and mass transport, 65–6
 - extracellular matrix, 63–5
 - three-dimensional versus two-dimensional structures, 55–8
- time duration of engineered tissues, 83–4
- time-based monitoring of cultures, 73

- time-dependent complexity increase, 66
- timing, importance of, 135
- tissue engineering and regenerative medicine (TERM), 1–2, 27–8, 179
 - bio-integration, 7–8
 - diversity of background, 8–10
 - teaching approaches, 9
 - control of tensional homeostasis, 173–4
 - cell-directed, 174–7
 - mechanically reactive collagen remodelling, 177–8
- definitions, 2–3
- levels, 6
- scale-hierarchy, 4–7
- summary, 28–30
- tissue engineering, 3–4
- differences between
 - repair versus regeneration, 20–3
 - replacement, repair and regeneration, 23–7
- future directions, 247–8
- general philosophies, 163–5
 - natural tissue growth, clues from, 166–7
 - reconstructive surgery, lessons from, 165–6
- growth, nature of, 167–9
 - adult growth, mechanically induced, 171–2
 - childhood growth, 169–70
 - childhood growth, mechanically induced, 170–1
 - shrinkage remodelling, 172–3
 - historical perspective, 16–20
- tension-driven growth in *in vivo* tissue engineering, 178
 - mechanical loading, 178–9
 - tribes, 10–13
 - networking, 13–16
- tissue models, 41–2
 - cell selection, 44–5
 - implants, 42–4
 - size, 46
 - support matrices, 45–6
 - three-dimensional, 42
- tissue prosthetics, 83–5
- top-down fabrication, 107–10
- top-down processed tissues, 97
- transformed cell lines, 45
- transforming growth factor- β (TGF- β), 99, 127
- tropocollagen, 95
 - gels, 97
- two-dimensional cell culture, 55

- ‘ungrowth’, 173

- vascular endothelial growth factor (VEGF), 99, 100, 115, 127
- vascular integration, 22
- Vesalius, Andreas, 18

- whole organ engineering, 6
- wide versus narrow approaches to problem solving, 164
- Wolff’s Law, 182